Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
-7°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Mainz BioMed NV
< Previous
1
2
Next >
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
February 06, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
January 11, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Provides Year-End Corporate Review 2023
January 09, 2024
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
December 19, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
December 12, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
December 05, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
November 29, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 16, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
November 15, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
November 13, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
November 09, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
November 07, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
October 31, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
October 26, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
October 18, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
October 11, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
October 05, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
October 04, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
September 27, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
September 13, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
September 05, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
August 29, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
August 22, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
August 15, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
ASX:MAP
MYNZ
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
August 01, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
July 18, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed Secures up to $50M in New Funding
June 29, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
June 28, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Tickers
MYNZ
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.